Also known as: formerly Maxamine
EpiCept (Licensor)Meda (Licensee)
EpiCept granted Meda exclusive rights to market Ceplene histamine dihydrochloride in Europe, Japan, China and Australia
EpiCept (Licensor)IDIS (Licensee)
EpiCept granted IDIS worldwide rights to manage a named-patient program for Ceplene histamine dihydrochloride outside the U.S.
Set Email Alert